Maternal antibody-mediated fetal red blood cell destruction secondary to non-D Rhesus (Rh) antibodies is a significant cause of hemolytic disease of the newborn (HDN). Here, we report a rare case of severe HDN associated with maternal antibody to Rh e. In addition to severe anemia, the infant developed thrombocytopenia, conjugated hyperbilirubinemia and cholelithiasis. Resolution of the infant's cholelithiasis occurred following treatment with ursodeoxycholic acid.
Introduction
In the era of Rhesus (Rh) immune globulin treatment, the non-D Rh antibodies are an increasingly significant cause of alloimmune hemolytic disease of the newborn (HDN). 1 While HDN due to anti-e has been sporadically reported in literature, it is not described as a cause of severe HDN. We report a case of HDN due to anti-e that resulted in severe hemolytic anemia and hyperbilirubinemia requiring exchange transfusion as well as cholestasis with cholelithiasis.
Case A female infant was born at 39 weeks of gestation by cesarean section due to non-reassuring fetal heart tones that progressed to a sinusoidal fetal heart rate pattern. Maternal history, prenatal labs and family history were unremarkable. The mother was a 31-yearold G2P1 of Hispanic descent. Her blood group was A Rh positive with a negative first-trimester antibody screen and no prior history of blood transfusion. The infant's birth weight was 3383 g and Apgar scores were 2, 5 and 7 at 1, 5 and 10 min of life, respectively. After birth, the infant was intubated and placed on mechanical ventilation secondary to respiratory distress and hypoxia. Persistent pulmonary hypertension was suspected secondary to differential oxygen saturations noted between the preductal arterial circulation (right upper extremity, 100% saturation) and the postductal arterial circulation (lower extremities, 83% saturation). Metabolic acidosis (pH of 7.19 with a base deficit of 18) was noted by an arterial catheter. Dopamine and dobutamine were started secondary to hypotension (mean arterial pressure 32-34 mm Hg). Ampicillin and gentamicin were started empirically for possible sepsis. The remarkable physical findings were as follows: nondysmorphic appearance; age-appropriate length and head circumference; jaundice; course breath sounds bilaterally but with good chest rise; a 2/6 systolic murmur at the left lower sternal border; heart rate, 145 to 165 per min; and hepatomegaly of 5 cm under costal margin with palpable spleen tip. Laboratory evaluation included complete blood count with hemoglobin, 5.4 g per 100 ml; nucleated red blood cells, 117 mm À3 ; corrected white blood cell, 37.6 Â 10 9 l À1 ; platelet count, 153 Â 10 9 l À1 ; red cell mean corpuscular volume, 138 fl; reticulocyte count, 19%; fibrinogen, 276 mg per 100 ml; prothrombin and active partial thromboplastin time normal. Peripheral blood smear revealed hemolytic findings, including increased nucleated red blood cells, reticulocytosis, polychromasia, anisocytosis and poikilocytosis. Infant blood group was A Rh positive and direct antiglobulin test positive. Her initial total serum bilirubin was 14.1 mg per 100 ml, with 6.6 mg per 100 ml of conjugated and 7.5 mg per 100 ml of unconjugated bilirubin. A timeline displaying her hemoglobin and bilirubin levels is shown in Figure 1 . Lactic dehydrogenase level was 13 421 U per l, total protein 4.3 g per 100 ml and albumin 2.3 g per 100 ml. Viral studies, Toxoplasma gondii, other microorganisms (for example, syphilis), rubella virus, cytomegalovirus and herpes simplex virus (TORCH screen) were negative. Repeat maternal antibody screen performed postpartum revealed Rh anti-e, and the father (a Caucasian male) was typed as Rh (D) positive, C positive, E negative, c negative and e positive.
The infant was treated with two transfusions of packed red blood cells (10 ml kg À1 each) at 3 and 16 h of life, secondary to severe anemia and hypotension. Her heart murmur disappeared and her persistent pulmonary hypertension clinically resolved following her first blood transfusion. An echocardiogram showed a patent ductus arteriosus and patent foramen ovale, both with left-to-right flow, systemic right ventricular pressures and depressed right ventricular function. She received a dose of human intravenous immune globulin (IVIG) and an isovolumetric double volume exchange transfusion with packed red blood cells (reconstituted in fresh frozen plasma with an adjusted hematocrit of 42%) for severe symptomatic anemia and hyperbilirubinemia. Intensive phototherapy was initiated because of her elevated total bilirubin level and suspected isoimmune process. She had a peak total bilirubin of 18.9 mg per 100 ml and unconjugated bilirubin of 7.8 mg per 100 ml at 22 h of life. On day of life 2, she received a second dose of IVIG to potentially avoid another exchange transfusion, was extubated to nasal cannula oxygen and was weaned off inotropic support. Her antibiotics were discontinued after 48 h, following negative blood-culture results. She developed thrombocytopenia requiring two platelet transfusions. On day of life 9, she was discharged from the neonatal intensive care unit and had a close outpatient follow-up. Owing to persistent conjugated hyperbilirubinemia, an abdominal ultrasound was obtained on day of life 20, demonstrating numerous echogenic layering gallstones within the gallbladder with a non-enlarged common bile duct. A hepatobiliary flow and function scan with technetium 99m diisopropyl-imino-diacetic acid displayed normal uptake but no small bowel excretion. She was treated with ursodeoxycholic acid, which was stopped after gallbladder ultrasound demonstrated resolution of cholelithiasis at 3 months of age. She required a simple blood transfusion on day of life 31 secondary to significant anemia. Her conjugated hyperbilirubinemia, which followed serially, was resolved by 3 months of age. Currently, she is doing well with normal development at 10 months of age.
Discussion
We present a case of severe HDN due to 'e' isoimmunization, the first such report to our knowledge. The mother's first pregnancy and delivery were uncomplicated, and her first child had no hyperbilirubinemia. She had no prior history of blood transfusion, a common cause of non-D isoimmunization. 2 With her second pregnancy, she was A positive with a negative antibody screen early in gestation and had an otherwise uncomplicated antenatal course until presenting at 38 weeks. When the newborn presented with significant anemia, the etiology was investigated. Despite a negative antibody screen, we performed a direct antiglobulin test to rule out isoimmunization from a minor blood group antigen, and a positive result for anti-e was reported. This underscores the importance of performing, in cases of congenital anemia, a direct antiglobulin test regardless of the mother's blood type or antibody screen.
The highly homologous RHD and RHCE genes, localized on chromosome lp34.3-p36.1, encode the Rh proteins, Rh D and Rh CE. 3, 4 One gene carries the D antigen and the other carries CE antigens in various combinations (ce, Ce, cE or CE), with the E and e antigens differing by one amino acid, Pro226Ala. 4 While all non-D Rh antigens (C, c, E and e) have been implicated as a cause of HDN, anti-e has been noted to be only weakly antigenic and not a significant cause of severe isoimmunization and hemolytic disease. 1, [5] [6] [7] [8] Although rare, the currently reported case illustrates that anti-e can cause severe HDN. Significant early-onset conjugated hyperbilirubinemia occasionally accompanies cases of isoimmunization. 9 In theory, direct bilirubin does not cross the blood-brain barrier and should not contribute to the risk of kernicterus. However, Maisels 10 reported three cases of kernicterus with significant elevation of direct bilirubin while indirect bilirubin was less than 20 mg per 100 ml. These infants were not given exchange transfusions, presumably because of the elevated direct fraction. Because the contribution of direct bilirubin to kernicterus is not clear, we based our decisions for phototherapy and exchange transfusion on the total level of bilirubin, in accordance with current clinical practice guidelines. 11 More chronically, severe hemolysis and conjugated hyperbilirubinemia have been noted to be predisposing factors to cholelithiasis in infancy, leading to biliary sludging and/or development of gallstones. 12 The best treatment approach for gallstones in the neonatal population remains unclear. Medical management with ursodeoxycholic acid, a hydrophilic dihydroxylated bile acid used in various chronic cholestatic liver diseases, is effective in resolving biliary sludging and gallstones. 13 In addition, conservative management may be appropriate with later pharmacologic treatment if symptoms persist. For conservative management, repeat ultrasounds to monitor the resolution of gallstones are required in addition to laboratory monitoring. All infants manifesting significant cholestasis should be evaluated and treated to prevent significant nutritional deficiencies resulting from reduced secretion of bile acids into the intestine.
In the last several years, IVIG has been used more commonly as a treatment for infants with HDN-associated jaundice. Two systemic reviews, a Cochrane Neonatal Review by Alcock and Liley 14 and a review by Gottstein and Cooke, 15 assessed the effectiveness of IVIG at reducing the need for exchange transfusion in newborn infants with isoimmune hemolytic jaundice secondary to Rh and ABO incompatibility. Both reviews showed a statistically significant reduction in both the incidence of exchange transfusion and the mean number of exchange transfusions required per infant in those treated with a combination of IVIG and phototherapy. 14, 15 Both the meta-analyses looked at the same three trials determining the impact of IVIG on the use of exchange transfusion, and although the studies could have been of higher quality, the known risks associated with exchange transfusion appear greater than those associated with IVIG. The current recommendations of the American Academy of Pediatrics (July 2004) 11 and the National Advisory Committee on Blood and Blood Products of Canada and Canadian Blood Services (April 2007) advice the use of IVIG for the treatment of HDN with established jaundice. 16 In summary, we report a case of an infant with anti-e isoimmunization, presenting at birth with severe symptomatic anemia and hyperbilirubinemia requiring an emergent exchange transfusion. In the presence of congenital anemia, clinicians need to consider obtaining a direct antiglobulin test regardless of the mother's blood type or antibody screen. Intravenous immune globulin therapy may have prevented a second exchange transfusion in this case, and its selective use for the treatment of isoimmune hemolytic jaundice should be considered only after weighing the risks and benefits associated with an exchange transfusion. Finally, hemolytic conjugated hyperbilirubinemia resulting in the development of gallstones was successfully treated with ursodeoxycholic acid.
